Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC

5mg once daily for 14 days on/7 days off, over a 21-day cycle

The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks.

TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days

Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days